一种结合获益与危害评估的新方法:将风湿病学结局指标3×3方法应用于两项活性对照试验
本研究将OMERACT 3×3方法应用于TEAR和RACAT两项随机试验的安全性数据,在个体患者层面同时分析获益与危害。TEAR试验755例中612例有48周应答数据,14%获无保留成功、9%为彻底失败,组间无差异;RACAT试验353例中309例有48周应答数据,6%获无保留成功、11%为彻底失败,组间无差异,且应答与不良事件率呈负相关(P=0.008)。作者认为有证据提示不良事件共存可能降低临床应答。
要点
- TEAR试验48周时14%患者无保留成功、9%彻底失败,治疗组间无差异。
- RACAT试验48周时6%患者无保留成功、11%彻底失败,治疗组间无差异。
- RACAT中应答与不良事件率呈负相关,不良事件及严重不良事件频率随应答降低而增加(P=0.008)。
核心结论
- 作者发现有证据提示临床应答可能因不良事件共存而降低。
研究设计与样本
- 将OMERACT 3×3方法应用于两项近期类风湿关节炎随机试验(TEAR和RACAT)的安全性数据,在个体患者层面同时分析获益与危害。
- 安全性按OMERACT定义为无不良事件、非严重不良事件和严重不良事件;疗效定义为良好、中等或无应答。
- 良好应答且无任何不良事件定义为无保留成功,无应答且至少1次不良事件定义为彻底失败。
- 获益与危害的关联酌情采用卡方检验或精确检验评估。
主要发现
- TEAR试验755例中612例有48周应答数据:14%患者经历无保留成功,9%经历彻底失败,治疗组间无差异;应答与不良事件率不相关。
- RACAT试验353例中309例有48周应答数据:6%患者经历无保留成功,11%经历彻底失败,治疗组间无差异;应答与不良事件率呈负相关。
- 不良事件和严重不良事件频率随应答降低而增加(P=0.008)。
关键数值与推荐
- TEAR试验755例中612例有48周应答数据。
- RACAT试验353例中309例有48周应答数据。
- RACAT中不良事件和严重不良事件频率随应答降低而增加(P=0.008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) 3×3 method analyzes the occurrence of benefit and harm simultaneously at the individual patient level. We applied this method to 2 recent rheumatoid arthritis (RA) trial data sets. METHODS: The Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) and the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) randomized trial outcomes for safety were defined according to OMERACT as having no adverse events (AEs), non-serious AEs, and serious AEs. Treatment efficacy was defined as good, moderate, or no response. A good treatment response without any AEs was labeled an unqualified success, and no treatment response but at least 1 AE was considered an unmitigated failure. The association between benefit and harm was assessed by chi-square or exact tests, as appropriate. RESULTS: In TEAR, 612 of 755 patients had response data at 48 weeks: 14% of patients experienced unqualified success and 9% had unmitigated failure, with no difference between the treatment arms. Treatment response and AE rates were not correlated. In RACAT, 309 of 353 patients had response data at 48 weeks: 6% of patients experienced unqualified success and 11% had unmitigated failure, with no differences between the treatment arms. Response and AE rates were negatively correlated. The frequency of AEs and serious AEs increased as response decreased (P = 0.008). CONCLUSION: We found some evidence that clinical response may be reduced by the co-occurrence of AEs.
引用
- Boers M, Singh JA, Cofield SS, et al. A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials. Arthritis Care Res (Hoboken). 2019. PMID: 29691998. doi:10.1002/acr.23590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。